Sec Form 3 Filing - Bergwerk Dov @ TEVA PHARMACEUTICAL INDUSTRIES LTD - 2023-10-13

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Bergwerk Dov 2. Issuer Name and Ticker or Trading Symbol TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Acting Chief Legal Officer (Last) (First) (Middle) C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.,, 124 DVORA HANEVI'A STREET 3. Date of Earliest Transaction (MM/DD/YY) 10/13/2023 (Street) TEL AVIV, L36944020 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares ( 1 ) 90,330 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Restricted Share Units ( 3 ) ( 2 ) ( 2 ) Ordinary Shares ( 1 ) 6,653 D Restricted Share Units ( 3 ) ( 4 ) ( 4 ) Ordinary Shares ( 1 ) 14,587 D Restricted Share Units ( 3 ) ( 5 ) ( 5 ) Ordinary Shares ( 1 ) 32,036 D Restricted Share Units ( 3 ) ( 6 ) ( 6 ) Ordinary Shares ( 1 ) 31,075 D Stock Options (right to buy) $ 48.76 ( 7 ) 03/12/2024 Ordinary Shares ( 1 ) 7,501 D Stock Options (right to buy) $ 60.21 ( 8 ) 03/12/2025 Ordinary Shares ( 1 ) 12,753 D Stock Options (right to buy) $ 53.5 ( 9 ) 03/17/2026 Ordinary Shares ( 1 ) 12,754 D Stock Options (right to buy) $ 34.7 ( 10 ) 03/03/2027 Ordinary Shares ( 1 ) 17,505 D Stock Options (right to buy) $ 28.98 ( 11 ) 05/24/2027 Ordinary Shares ( 1 ) 8,755 D Stock Options (right to buy) $ 19.16 ( 12 ) 03/02/2028 Ordinary Shares ( 1 ) 27,501 D Stock Options (right to buy) $ 16.99 ( 13 ) 09/18/2027 Ordinary Shares ( 1 ) 7,010 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Bergwerk Dov C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A STREET TEL AVIV, L36944020 Acting Chief Legal Officer Signatures /s/ Dov Bergwerk 10/18/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The Ordinar y Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. ( 2 )Restricted share units were granted on February 28, 2020, with 6,653 vesting on February 28, 2024. ( 3 )Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resourcesand Compensation Committee, the cash value of one ordinary share. ( 4 )Restricted share units were granted on March 5, 2021, with 7,293 vesting on March 5, 2024 and 7,294 vesting on March 5, 2025. ( 5 )Restricted share units were granted on March 4, 2022, with 10,678 vesting on each of March 4, 2024 and March 4, 2025 and 10,680 vesting on March 4, 2026. ( 6 )Restricted share units were granted on March 3, 2023, with 7,768 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026 and 7,771 vesting on March 3, 2027. ( 7 )Stock options were granted on March 12, 2014, with 2,500 having vested on each of March 12, 2015 and March 12, 2016 and 2,501 having vested on March 12, 2017. ( 8 )Stock options were granted on March 12, 2015, with 3,188 having vested on each of March 12, 2016, March 12, 2017 and March 12, 2018 and 3,189 having vested on March 12, 2019. ( 9 )Stock options were granted on March 17, 2016, with 3,188 having vested on each of March 17, 2017, March 17, 2018 and March 17, 2019 and 3,190 having vested on March 17, 2020. ( 10 )Stock options were granted on March 3, 2017, with 4,376 having vested on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 4,377 having vested on March 3, 2021. ( 11 )Stock options were granted on May 24, 2017, with 2,188 having vested on each of May 24, 2018, May 24, 2019 and May 24, 2020 and 2,191 having vested on May 24, 2021. ( 12 )Stock options were granted on March 2, 2018, with 6,875 having vested on each of March 2, 2019, March 2, 2020 and March 2, 2021 and 6,876 having vested onMarch 2, 2022. ( 13 )Restricted share units were granted on September 18, 2017, with 3,505 having vested on each of September 18, 2018 September 18, 2019.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.